SequelSEC

Nuvation Bio Inc. NUVB

Pharmaceutical Preparations · CIK 0001811063 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$169.90M
Fiscal year ended 2026-06-30
Operating income
-$137.63M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$496.97MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float / revenue7.9×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.6×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth699.0%95th
Current ratio6.95x70th
SBC / revenue57.1%64th
Net margin-325.3%43th
Operating margin-338.7%46th
R&D / revenue183.0%50th

Nuvation Bio Inc. (NUVB) reported revenue of $169.90M and net income of -$149.83M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Nuvation Bio Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Nuvation Bio Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$169.90M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$137.63M
Net income-$149.83M
Research & development$128.85M
Weighted-average diluted sharesUnavailable
Pretax income-$149.83M
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrative$158.58M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Nuvation Bio Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$258.60M
Total assets$744.50M
Current assets$726.43M
Total liabilities$490.64M
Current liabilities$86.76M
Total equity incl. NCI$253.86M
Temporary (mezzanine) equityUnavailable
Inventory$19.90M
Accounts receivable$27.83M
GoodwillUnavailable
Long-term debt$242.62M
Accounts payable$12.09M

Cash flow

Nuvation Bio Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$120.52M
Capital expendituresUnavailable
Investing cash flow-$47.18M
Financing cash flow$179.14M
Net change in cash$10.63M
Stock-based compensation$35.50M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.14M

Derived

Nuvation Bio Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-81.0%
FCF marginUnavailable
SBC / revenue20.9%
Current ratio8.37x
Revenue YoY growth1083.6%
Net margin-88.2%
R&D / revenue75.8%
CapEx / revenueUnavailable
Long-term debt / equity0.96x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NUVB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.